Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
Casey
Daniel E
DE
Haupt
Dan W
DW
Newcomer
John W
JW
Henderson
David C
DC
Sernyak
Michael J
MJ
Davidson
Michael
M
Lindenmayer
Jean-Pierre
JP
Manoukian
Steven V
SV
Banerji
Mary Ann
MA
Lebovitz
Harold E
HE
Hennekens
Charles H
CH
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality; D002423:Cause of Death; D016883:Diabetic Ketoacidosis / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality; D007333:Insulin Resistance; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality; D009203:Myocardial Infarction / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality; D015995:Prevalence; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000401:mortality*; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents